The 2026 Healthtech Messaging Index
BrightInsight
brightinsight.com·scored September 1, 2026
30/38
Approaching
Close. The bones are good. A few targeted fixes on the weakest signals would push BrightInsight into magnetic territory.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for Patient persistence and therapy adherence platform for pharma brands, it named:
Buyer we put in the prompt: Brand General Manager or VP of Patient Services at a mid-to-large pharmaceutical or biotech company launching or managing a novel therapy. Both the buyer and the category were inferred from BrightInsight’s homepage alone. The model had no web access.
BrightInsight was not on the list.
A buyer who asked AI this question got 8 names and moved on. BrightInsight never came up.
We asked AI who it recommends for "Brand General Manager or VP of Patient Services at a mid-to-large pharmaceutical or biotech company launching or managing a novel therapy" looking for "Patient persistence and therapy adherence platform for pharma brands". It named Adheris Health, Lash Group, ConnectiveRx, Welltok, Healthmap Solutions. You did not appear. AI can't recommend what it can't clearly understand.
Overall assessment
BrightInsight's biggest strength is its razor-sharp problem framing: the 'persistence crisis' is named, quantified at $500B+, and backed by a real Sanofi outcome ... this is one of the most evidence-anchored pharma homepages you'll encounter. The biggest gap is trust architecture: there are zero named testimonials with titles, no competitive acknowledgment, and no founder or institutional authority signals, so buyers who need social validation before contacting sales hit a wall.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or 'do nothing' as an option anywhere on the page.”
The page never acknowledges what buyers might do instead ... internal builds, CRM workarounds, or competing vendors ... missing a trust-building opportunity entirely.
All 19 signals, scored 0 to 2.
Total 30/38
Narrative Clarity
8 signals
- 2
01The 7-Second Test
“BrightInsight is the patient persistence solution that predicts and prevents therapy drop-off ... before it happens.”
Within seconds, a stranger understands this is for pharma brands, the problem is patients quitting therapy, and the POV is predictive prevention ... clear enough for a caveman.
- 2
02Rebellion / Movement
“the persistence crisis steals health from patients and $500B+ in annual value from brands every year”
The page names a specific enemy ... 'the persistence crisis' ... and calls out existing systems as complicit: 'closes the gap your existing systems were never designed to fill.'
- 2
03Owned Language & Category
“BrightInsight is the patient persistence solution... The Leaky Bucket: The Pharma Industry's Greatest Hidden Threat”
The page owns 'patient persistence solution' as a named category and coins 'the persistence crisis' and 'the leaky bucket' as proprietary frames an AI could quote back.
- 1
04ICP Clarity
“brands that reclaim the revenue their science was built to generate”
The buyer is clearly a pharma brand, but role specificity (VP Patient Services? Brand GM? CMO?) and company size/stage are never named, leaving ICP only half-resolved.
- 2
05Problem Leadership
“fewer than 1 in 3 patients still on a novel therapy at 12 months”
The page leads with a stark, quantified buyer problem before pitching the solution, putting the crisis front and center above any product description.
- 2
06Solution Clarity
“unifies the patient experience, detects the behavioral signals that precede discontinuation, and triggers the right intervention at the moments that matter most”
A visitor can repeat exactly what BrightInsight does in one sentence after reading the hero ... unify signals, detect drop-off risk, intervene in time.
- 2
07Cost of Inaction
“$500B+ in annual value from brands every year”
The page names the dollar cost of inaction explicitly ... $500B+ lost annually ... and frames it as recurring revenue destruction, making the stakes undeniable.
- 2
08Promised Land
“patients who stay on therapy longer, and brands that reclaim the revenue their science was built to generate”
The promised land is concrete on both axes ... patient health outcomes and brand revenue recovery ... giving buyers a vivid 'after' state to desire.
Trust Signal
4 signals
- 2
09Proof & Evidence
“reduced discontinuation by 4% and boosted adherence by 4% in one year for Sanofi”
Specific before/after deltas with a named partner in a defined timeframe ... this is real proof, not adjectives.
- 1
10Social Proof
“One Year In, More Than 80% of Macular Disease Patients at Stanford Health Care Were Still Using the myVisionTrack App”
Sanofi and Stanford are named with real outcomes, but there are no testimonials with named individuals, titles, or quotes ... social proof is logo/result level only.
- 1
11Authority & Credibility
“No founder credentials, original research citations, awards, or analyst recognition on the page.”
The Sanofi and Stanford results demonstrate credibility by association, but the page never establishes who built this, what proprietary research backs it, or any third-party authority signal.
- 0
12Alternatives Acknowledgedweakest
“No mention of competitors, alternative approaches, or 'do nothing' as an option anywhere on the page.”
The page never acknowledges what buyers might do instead ... internal builds, CRM workarounds, or competing vendors ... missing a trust-building opportunity entirely.
AI Signal
6 signals
- 2
13Customer Focus
“patients who stay on therapy longer, and brands that reclaim the revenue their science was built to generate”
The page consistently frames both patients and pharma brands as protagonists experiencing transformation, not BrightInsight as the hero of its own story.
- 2
14AI-Parmesan Index
“detects the behavioral signals that precede discontinuation, and triggers the right intervention at the moments that matter most”
There is no gratuitous 'AI-powered' sprinkle; where intelligence is implied, it is described mechanistically ... behavioral signal detection and intervention triggering ... earning a clean score.
- 2
15LLM Quotability
“fewer than 1 in 3 patients still on a novel therapy at 12 months, the persistence crisis steals health from patients and $500B+ in annual value”
Multiple declarative, statistic-anchored sentences are structured exactly as an LLM would lift them verbatim to answer 'what problem does BrightInsight solve?'
- 2
16Copyright Freshness
“Jun 12, 2026... Jun 01, 2026... Press Release / May 07, 2026”
Three pieces of content with explicit, recent dates are visible on the homepage, providing strong recency signals for AI crawlers.
- 2
17Entity Distinctiveness
“BrightInsight is the patient persistence solution that predicts and prevents therapy drop-off ... before it happens”
The combination of 'patient persistence,' '$500B+ persistence crisis,' named pharma partners, and behavioral signal detection makes this positioning unmistakably distinct ... swapping the logo would break the description.
- 0
18AI Recommendation Check
“AI's picks: Adheris Health, Lash Group, ConnectiveRx, Welltok, Healthmap Solutions, Propeller Health. You were not named.”
We asked AI who it recommends for "Brand General Manager or VP of Patient Services at a mid-to-large pharmaceutical or biotech company launching or managing a novel therapy" looking for "Patient persistence and therapy adherence platform for pharma brands". It named Adheris Health, Lash Group, ConnectiveRx, Welltok, Healthmap Solutions. You did not appear. AI can't recommend what it can't clearly understand.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“Contact us today to start a conversation... [Learn more] links appear twice above the CTA”
There is one primary CTA ('Contact us') and a soft 'Learn more,' but no visible numbered process or pathway connecting them ... the conversion path exists but isn't structured or explained.
Your move
Think BrightInsight’s score is wrong? Good. Let’s look at it together.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing BrightInsight the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.